{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(6)"],"submitter":["Borley AC"],"pubmed_abstract":["<h4>Introduction</h4>Anti-oestrogens have been the mainstay of therapy in patients with oestrogen-receptor (ER) positive breast cancer and have provided significant improvements in survival. However, their benefits are limited by tumour recurrence in a significant proportion of initially drug-responsive breast cancer patients because of acquired anti-oestrogen resistance. Relapse on such therapies clinically presents as local and/or regional recurrences, frequently with distant metastases, and the prognosis for these patients is poor. The selective ER modulator, tamoxifen, classically exerts gene inhibitory effects during the drug-responsive phase in ER-positive breast cancer cells. Paradoxically, this drug is also able to induce the expression of genes, which in the appropriate cell conte"],"journal":["Breast cancer research : BCR"],"pagination":["R103"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC2656899"],"repository":["biostudies-literature"],"pubmed_title":["Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells."],"pmcid":["PMC2656899"],"pubmed_authors":["Barrett-Lee P","Nicholson RI","Smith C","Gee J","Borley AC","Shaw V","Hiscox S"],"additional_accession":[]},"is_claimable":false,"name":"Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells.","description":"<h4>Introduction</h4>Anti-oestrogens have been the mainstay of therapy in patients with oestrogen-receptor (ER) positive breast cancer and have provided significant improvements in survival. However, their benefits are limited by tumour recurrence in a significant proportion of initially drug-responsive breast cancer patients because of acquired anti-oestrogen resistance. Relapse on such therapies clinically presents as local and/or regional recurrences, frequently with distant metastases, and the prognosis for these patients is poor. The selective ER modulator, tamoxifen, classically exerts gene inhibitory effects during the drug-responsive phase in ER-positive breast cancer cells. Paradoxically, this drug is also able to induce the expression of genes, which in the appropriate cell conte","dates":{"release":"2008-01-01T00:00:00Z","publication":"2008","modification":"2025-04-04T19:12:53.586Z","creation":"2019-03-27T00:21:17Z"},"accession":"S-EPMC2656899","cross_references":{"pubmed":["19055788"],"doi":["10.1186/bcr2206"]}}